• レポートコード:TMRGL26735 • 出版社/出版日:Transparency Market Research / 2022年11月16日 • レポート形態:英文、PDF、250ページ • 納品方法:Eメール • 産業分類:医療 |
Single User | ¥869,250 (USD5,795) | ▷ お問い合わせ |
Multi User | ¥1,319,250 (USD8,795) | ▷ お問い合わせ |
Corporate License | ¥1,769,250 (USD11,795) | ▷ お問い合わせ |
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
※当レポートは英文です。下記の日本語概要・目次は自動翻訳を利用し作成されました。正確な概要・目次はお問い合わせフォームからサンプルを請求してご確認ください。
2017年から2021年までの間葉系幹細胞(MSC)の販売分析 Vs 2022年から2032年までの市場展望
間葉系幹細胞(MSC)の世界市場は、2017~2021年の期間にCAGR14.7%で拡大しました。また、2032年末までにCAGR17.3%で躍進し、164億米ドルの売上を記録すると予測されています。
なぜ間葉系幹細胞(MSC)市場は急成長しているのか?
間葉系幹細胞(MSC)は、自己再生能力を持ち、多系統の分化を示すストローマ細胞で、その重要性や用途を分析する研究や調査が増えるにつれ、人気が高まっています。間葉系幹細胞は、臍帯、骨髄、脂肪組織など、さまざまな分離源から得られます。月経血や子宮内膜のようなソースからこれらの細胞が発見されたこともある。ヒトMSCは入手しやすく、大量に採取することも比較的容易であり、培養も可能である。また、免疫抑制性、自己複製性、抗炎症性などの特徴を持つことから、広く利用されています。
MSCの使用に関する研究と応用の拡大、およびこの研究のための資金の大幅な増加は、市場の主要な推進要因になると予想されます。ARDSなどのCOVID-19合併症の治療におけるMSCの可能性は、研究を増加させ、したがってその需要も増加しています。さらに、メーカーは、試験の成功による潜在的な需要を満たすために、MSCの商業グレードの生産のための技術の向上を検討しています。
地域別インサイト
北米は間葉系幹細胞(MSC)の需要にどのように貢献しているのでしょうか?
北米はMSCの需要に大きく寄与しており、米国だけで市場需要の45%以上を占めています。特にCOVID-19の治療への応用において、多数の主要企業の立地と集中的な資金調達の増加が需要に影響を与えています。
2020年4月、カナダ政府が支援するカナダの幹細胞ネットワークは、COVID-19に関連する3つのプロジェクトへの資金提供を発表しました。そのうちの1つ「COVID-19誘発急性呼吸窮迫症候群に対する細胞免疫療法:CIRCA-19試験」は、COVID-19患者に認められる急性呼吸窮迫に対する治療法としてMSCを使用するための臨床試験を実施するために30万米ドルを獲得したものです。
2022年6月には、資金調達コンペの結果、様々なプロジェクトに22.4Mn米ドルを配分したことを発表しました。敗血症性ショックに対する細胞性免疫療法としての臍帯間葉系幹細胞の使用に関する研究は、第II相RCTのために999,850米ドルが授与されました。
2021年10月、FDAは、希少疾患のケアのためのpf医薬品の支援のため、11種類の臨床試験に対して25百万米ドルの資金提供を発表しました。そのうちの1つは、メイヨークリニック・ロチェスターの「多系統萎縮症の治療のための自己間葉系幹細胞の髄腔内投与」研究のフェーズ2であった。
国別インサイト
中国間葉系幹細胞(MSC)市場の分析
中国は、世界の間葉系幹細胞(MSC)の中で2番目に大きな市場であり、市場規模は23億米ドル、2022年から2032年の間にCAGR22.7%で成長すると予測され、20億米ドルの絶対額の機会を記録しています。
幹細胞研究に対する大規模な中央支援と質の高い研究センターの存在が、成長の主な理由です。中国国家自然科学基金によると、1997年から2019年の間に、5億7600万米ドルの資金が幹細胞プログラムに授与されました。
米国の間葉系幹細胞(MSC)市場の分析
米国は、間葉系幹細胞(MSC)の最大の市場となることが予想されます。米国の間葉系幹細胞市場は、2022年〜2032年の間にCAGR17.4%で成長し、2032年には76億米ドルの市場規模に達すると予測されます。2022年から2032年にかけての市場の絶対額は61億米ドルに達すると予想されています。
英国間葉系幹細胞(MSC)市場の分析
英国の間葉系幹細胞(MSC)市場は、2022年〜2032年の間にCAGR19.5%で成長し、6億4360万米ドルの評価額に達すると予測されます。同国の市場は、534.7Mnドルの絶対的なドル機会を総計すると予想されます。
韓国の間葉系幹細胞(MSC)市場の分析
韓国の間葉系幹細胞(MSC)市場は、2032年までに276Mnの市場規模を記録すると予測されます。同市場は2022年から2032年の間に、CAGR16%を記録しながら214Mnドルの絶対的な機会利益を生み出すと予測されています。
カテゴリー別インサイト
どのタイプの間葉系幹細胞(MSC)が市場の需要を牽引しているのでしょうか?
CAGR14.3%を記録し、今後10年間のCAGRが14.7%と予測されている同種移植幹細胞が、間葉系幹細胞(MSC)のトップタイプであると言えます。自家用MSCは、細胞に対する免疫反応がないため安全な選択肢であるが、いくつかの制約があります。
特に、高齢者や合併症のある患者さんが多いため、必要な量を確保することが難しい、あるいは不可能な場合があり、得られたMSCも効率が悪い可能性が高く、また、抽出と膨張のプロセスには時間がかかるため、緊急時の応用には限界があります。一方、同種幹細胞は、事前にスクリーニングされたドナーから得られ、大規模に製造され、緊急事態に必要な分析および使用が可能です。
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. Value Chain Analysis
3.5.1. Profit Margin Analysis
3.5.2. Service Providers
3.6. PESTLE and Porter’s Analysis
3.7. Regulatory Landscape
3.7.1. By Key Regions
3.7.2. By Key Countries
3.8. Regional Parent Market Outlook
4. Global Mesenchymal Stem Cells Market Analysis 2017-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Bn) Analysis, 2017-2021
4.2. Current and Future Market Size Value (US$ Bn) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Mesenchymal Stem Cells Market Analysis 2017-2021 and Forecast 2022-2032, By Component
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Bn) Analysis By Component, 2017-2021
5.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Component, 2022-2032
5.3.1. Product
5.3.1.1. Workflow Type
5.3.1.2. Product Type
5.3.2. Service
5.4. Y-o-Y Growth Trend Analysis By Component, 2017-2021
5.5. Absolute $ Opportunity Analysis By Component, 2022-2032
6. Global Mesenchymal Stem Cells Market Analysis 2017-2021 and Forecast 2022-2032, By Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Bn) Analysis By Type, 2017-2021
6.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Type, 2022-2032
6.3.1. Autologous
6.3.2. Allogeneic
6.4. Y-o-Y Growth Trend Analysis By Type, 2017-2021
6.5. Absolute $ Opportunity Analysis By Type, 2022-2032
7. Global Mesenchymal Stem Cells Market Analysis 2017-2021 and Forecast 2022-2032, By Source of Isolation
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Bn) Analysis By Source of Isolation, 2017-2021
7.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Source of Isolation, 2022-2032
7.3.1. Bone Marrow
7.3.2. Cord Blood
7.3.3. Peripheral Blood
7.3.4. Fallopian Tube
7.3.5. Fetal Liver
7.3.6. Lung
7.3.7. Adipose Tissues
7.4. Y-o-Y Growth Trend Analysis By Source of Isolation, 2017-2021
7.5. Absolute $ Opportunity Analysis By Source of Isolation, 2022-2032
8. Global Mesenchymal Stem Cells Market Analysis 2017-2021 and Forecast 2022-2032, By Indication
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Bn) Analysis By Indication , 2017-2021
8.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Indication , 2022-2032
8.3.1. Bone And Cartilage Repair
8.3.2. Cardiovascular Disease
8.3.3. Inflammatory And Immunological Diseases
8.3.4. Liver Diseases
8.3.5. Cancer
8.3.6. GvHD
8.3.7. Other Indications
8.4. Y-o-Y Growth Trend Analysis By Indication , 2017-2021
8.5. Absolute $ Opportunity Analysis By Indication , 2022-2032
9. Global Mesenchymal Stem Cells Market Analysis 2017-2021 and Forecast 2022-2032, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ Bn) Analysis By Region, 2017-2021
9.3. Current Market Size Value (US$ Bn) Analysis and Forecast By Region, 2022-2032
9.3.1. North America
9.3.2. Latin America
9.3.3. Europe
9.3.4. Asia Pacific
9.3.5. MEA
9.4. Market Attractiveness Analysis By Region
10. North America Mesenchymal Stem Cells Market Analysis 2017-2021 and Forecast 2022-2032, By Country
10.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
10.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032
10.2.1. By Country
10.2.1.1. Value (US$ Bn)ed States
10.2.1.2. Canada
10.2.2. By Component
10.2.3. By Type
10.2.4. By Source of Isolation
10.2.5. By Indication
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Component
10.3.3. By Type
10.3.4. By Source of Isolation
10.3.5. By Indication
10.4. Key Takeaways
11. Latin America Mesenchymal Stem Cells Market Analysis 2017-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
11.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Component
11.2.3. By Type
11.2.4. By Source of Isolation
11.2.5. By Indication
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Component
11.3.3. By Type
11.3.4. By Source of Isolation
11.3.5. By Indication
11.4. Key Takeaways
12. Europe Mesenchymal Stem Cells Market Analysis 2017-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
12.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. U.K.
12.2.1.3. France
12.2.1.4. Spain
12.2.1.5. Italy
12.2.1.6. Russia
12.2.1.7. Rest of Europe
12.2.2. By Component
12.2.3. By Type
12.2.4. By Source of Isolation
12.2.5. By Indication
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Component
12.3.3. By Type
12.3.4. By Source of Isolation
12.3.5. By Indication
12.4. Key Takeaways
13. Asia Pacific Mesenchymal Stem Cells Market Analysis 2017-2021 and Forecast 2022-2032, By Country
13.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
13.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. India
13.2.1.4. South Korea
13.2.1.5. Australia
13.2.1.6. Rest of APAC
13.2.2. By Component
13.2.3. By Type
13.2.4. By Source of Isolation
13.2.5. By Indication
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Component
13.3.3. By Type
13.3.4. By Source of Isolation
13.3.5. By Indication
13.4. Key Takeaways
14. MEA Mesenchymal Stem Cells Market Analysis 2017-2021 and Forecast 2022-2032, By Country
14.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
14.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032
14.2.1. By Country
14.2.1.1. South Africa
14.2.1.2. Saudi Arabia
14.2.1.3. UAE
14.2.1.4. Israel
14.2.1.5. Rest of MEA
14.2.2. By Component
14.2.3. By Type
14.2.4. By Source of Isolation
14.2.5. By Indication
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Component
14.3.3. By Type
14.3.4. By Source of Isolation
14.3.5. By Indication
14.4. Key Takeaways
15. Key Countries Mesenchymal Stem Cells Market Analysis
15.1. Value (US$ Bn)ed States
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2021
15.1.2.1. By Component
15.1.2.2. By Type
15.1.2.3. By Source of Isolation
15.1.2.4. By Indication
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2021
15.2.2.1. By Component
15.2.2.2. By Type
15.2.2.3. By Source of Isolation
15.2.2.4. By Indication
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2021
15.3.2.1. By Component
15.3.2.2. By Type
15.3.2.3. By Source of Isolation
15.3.2.4. By Indication
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2021
15.4.2.1. By Component
15.4.2.2. By Type
15.4.2.3. By Source of Isolation
15.4.2.4. By Indication
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2021
15.5.2.1. By Component
15.5.2.2. By Type
15.5.2.3. By Source of Isolation
15.5.2.4. By Indication
15.6. U.K.
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2021
15.6.2.1. By Component
15.6.2.2. By Type
15.6.2.3. By Source of Isolation
15.6.2.4. By Indication
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2021
15.7.2.1. By Component
15.7.2.2. By Type
15.7.2.3. By Source of Isolation
15.7.2.4. By Indication
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2021
15.8.2.1. By Component
15.8.2.2. By Type
15.8.2.3. By Source of Isolation
15.8.2.4. By Indication
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2021
15.9.2.1. By Component
15.9.2.2. By Type
15.9.2.3. By Source of Isolation
15.9.2.4. By Indication
15.10. Russia
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2021
15.10.2.1. By Component
15.10.2.2. By Type
15.10.2.3. By Source of Isolation
15.10.2.4. By Indication
15.11. China
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2021
15.11.2.1. By Component
15.11.2.2. By Type
15.11.2.3. By Source of Isolation
15.11.2.4. By Indication
15.12. Japan
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2021
15.12.2.1. By Component
15.12.2.2. By Type
15.12.2.3. By Source of Isolation
15.12.2.4. By Indication
15.13. India
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2021
15.13.2.1. By Component
15.13.2.2. By Type
15.13.2.3. By Source of Isolation
15.13.2.4. By Indication
15.14. South Korea
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2021
15.14.2.1. By Component
15.14.2.2. By Type
15.14.2.3. By Source of Isolation
15.14.2.4. By Indication
15.15. Australia
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2021
15.15.2.1. By Component
15.15.2.2. By Type
15.15.2.3. By Source of Isolation
15.15.2.4. By Indication
15.16. South Africa
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2021
15.16.2.1. By Component
15.16.2.2. By Type
15.16.2.3. By Source of Isolation
15.16.2.4. By Indication
15.17. Saudi Arabia
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2021
15.17.2.1. By Component
15.17.2.2. By Type
15.17.2.3. By Source of Isolation
15.17.2.4. By Indication
15.18. UAE
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2021
15.18.2.1. By Component
15.18.2.2. By Type
15.18.2.3. By Source of Isolation
15.18.2.4. By Indication
15.19. Israel
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2021
15.19.2.1. By Component
15.19.2.2. By Type
15.19.2.3. By Source of Isolation
15.19.2.4. By Indication
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Component
16.3.3. By Type
16.3.4. By Source of Isolation
16.3.5. By Indication
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Thermo Fisher Scientific
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.1.5.2. Product Strategy
17.1.1.5.3. Channel Strategy
17.1.2. Cell Applications, Inc.
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.2.5.2. Product Strategy
17.1.2.5.3. Channel Strategy
17.1.3. Cyagen Biosciences
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.3.5.2. Product Strategy
17.1.3.5.3. Channel Strategy
17.1.4. Axol Biosciences Ltd.
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.4.5.2. Product Strategy
17.1.4.5.3. Channel Strategy
17.1.5. Cytori Therapeutics Inc.
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.5.5.2. Product Strategy
17.1.5.5.3. Channel Strategy
17.1.6. Stemcell Technologies Inc
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.6.5.2. Product Strategy
17.1.6.5.3. Channel Strategy
17.1.7. Celprogen Inc
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.7.5.2. Product Strategy
17.1.7.5.3. Channel Strategy
17.1.8. Brainstorm Cell Therapeutics Inc
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.8.5.2. Product Strategy
17.1.8.5.3. Channel Strategy
17.1.9. Stemedica Cell Technologies, Inc.
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.9.5.2. Product Strategy
17.1.9.5.3. Channel Strategy
17.1.10. Merck Millipore
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
17.1.10.5.2. Product Strategy
17.1.10.5.3. Channel Strategy
17.1.11. Smith & Nephew
17.1.11.1. Overview
17.1.11.2. Product Portfolio
17.1.11.3. Profitability by Market Segments
17.1.11.4. Sales Footprint
17.1.11.5. Strategy Overview
17.1.11.5.1. Marketing Strategy
17.1.11.5.2. Product Strategy
17.1.11.5.3. Channel Strategy
17.1.12. Lonza AG
17.1.12.1. Overview
17.1.12.2. Product Portfolio
17.1.12.3. Profitability by Market Segments
17.1.12.4. Sales Footprint
17.1.12.5. Strategy Overview
17.1.12.5.1. Marketing Strategy
17.1.12.5.2. Product Strategy
17.1.12.5.3. Channel Strategy
17.1.13. PromoCell GMBH
17.1.13.1. Overview
17.1.13.2. Product Portfolio
17.1.13.3. Profitability by Market Segments
17.1.13.4. Sales Footprint
17.1.13.5. Strategy Overview
17.1.13.5.1. Marketing Strategy
17.1.13.5.2. Product Strategy
17.1.13.5.3. Channel Strategy
17.1.14. Sciencell Research Laboratories
17.1.14.1. Overview
17.1.14.2. Product Portfolio
17.1.14.3. Profitability by Market Segments
17.1.14.4. Sales Footprint
17.1.14.5. Strategy Overview
17.1.14.5.1. Marketing Strategy
17.1.14.5.2. Product Strategy
17.1.14.5.3. Channel Strategy
17.1.15. American Type Culture Collection
17.1.15.1. Overview
17.1.15.2. Product Portfolio
17.1.15.3. Profitability by Market Segments
17.1.15.4. Sales Footprint
17.1.15.5. Strategy Overview
17.1.15.5.1. Marketing Strategy
17.1.15.5.2. Product Strategy
17.1.15.5.3. Channel Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
List of Tables
Table 1: Global Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Region, 2017-2032
Table 2: Global Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Component, 2017-2032
Table 3: Global Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Type, 2017-2032
Table 4: Global Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Source of Isolation, 2017-2032
Table 5: Global Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Indication , 2017-2032
Table 6: North America Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Country, 2017-2032
Table 7: North America Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Component, 2017-2032
Table 8: North America Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Type, 2017-2032
Table 9: North America Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Source of Isolation, 2017-2032
Table 10: North America Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Indication , 2017-2032
Table 11: Latin America Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Country, 2017-2032
Table 12: Latin America Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Component, 2017-2032
Table 13: Latin America Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Type, 2017-2032
Table 14: Latin America Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Source of Isolation, 2017-2032
Table 15: Latin America Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Indication , 2017-2032
Table 16: Europe Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Country, 2017-2032
Table 17: Europe Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Component, 2017-2032
Table 18: Europe Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Type, 2017-2032
Table 19: Europe Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Source of Isolation, 2017-2032
Table 20: Europe Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Indication , 2017-2032
Table 21: Asia Pacific Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Country, 2017-2032
Table 22: Asia Pacific Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Component, 2017-2032
Table 23: Asia Pacific Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Type, 2017-2032
Table 24: Asia Pacific Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Source of Isolation, 2017-2032
Table 25: Asia Pacific Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Indication , 2017-2032
Table 26: MEA Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Country, 2017-2032
Table 27: MEA Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Component, 2017-2032
Table 28: MEA Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Type, 2017-2032
Table 29: MEA Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Source of Isolation, 2017-2032
Table 30: MEA Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Indication , 2017-2032